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Water-soluble fullerenes for medical
applications
I. Rašovic∗́
Research on fullerenes occupies a unique position in the scientiﬁc arena. Synthesis and
characterisation of this nanomaterial blur the line between materials science and chemistry;
careful tuning of the processing methods gives birth to a whole family of molecules and their
functionalised derivatives, whose unusual properties at this nanoscopic scale can be exploited
in cutting-edge technological applications. This review focuses on the functionalisation of
fullerenes for use in medical applications. The ﬁrst half gives an introduction to the fullerenes
themselves and how their fundamental properties lead to a very rich chemistry, enabling both
exohedral (external) and endohedral (internal) functionalisations of the cage. Emphasis is placed
on the need for safe and reproducible synthesis routes if fullerenes are ever going to make it to
the pharmaceutical market. In line with this, a selection of exohedral functionalisation protocols
receives particular attention. Coverage of endohedral fullerene synthesis routes is limited to the
endohedral metallofullerenes. In the second half, myriad applications of fullerenes in biomedical
contexts are introduced and certain synthesis routes are critically evaluated. Discussion of the
need to water solubilise the hydrophobic fullerene cages precedes an overview of fullerene-
based diagnostic and therapeutic technologies. A ﬁnal moment is spent on toxicity studies of
fullerenes. The concluding remarks emphasise the positive effects of incorporating fullerenes
into biomedical technologies, while looking at how these are perceived by the general public. A
case is made for fullerenes being the optimal choice as standard bearers in the advance of
nanomaterials into the medical ﬁeld.
Keywords: Fullerenes, Water solubility, Functionalisation, Nanomedicine
This is the winning review of the 2016 Materials Literature Review Prize of the Institute of Materials, Minerals and Mining, run by the Editorial
Board of MST. Sponsorship of the prize by TWI Ltd is gratefully acknowledged.
Fullerenes
Why so interesting?
The fullerenes constitute a distinct allotrope in the family
of carbon nanomaterials. Their unique cage-like structure
and electron-deﬁcient nature lead to fascinating properties
which have made them a promising focus of research in an
array of ﬁelds. The most abundant fullerene, C60, has avan
der Waals diameter of 10.18 Å,1 positioning it well within
the realm of nanotechnology. The origin of the fullerenes’
key properties and rich chemistry lies in the unique hybrid-
isation of the strained carbon–carbon bonds;while the car-
bon atoms in graphene and carbon nanotubes (CNTs) are
sp2-hybridised to give hexagonal networks, and the tetra-
hedral networkof diamond is sp3-hybridised, the fullerenes
are made up of a network of both hexagons (1,3,5-cyclo-
hexatriene1) and pentagons ([5]radialene), as shown in
Fig. 1, leading to an average hybridisation of sp2.278.3
The presence of pentagonal rings introduces a signiﬁcant
amount of strain into the network,2 leading to a rehybri-
dised three-dimensional structure with asymmetric π orbi-
tals and thus three crucial properties.4 First, the fullerenes
are excellent electron acceptors, with C60 exhibiting six
reversible reductions. 5 Second, the exterior of the cages
can be decorated using a vast range of chemical reactions.
Finally, the relative inertness of the interior of the cages
facilitates the capture and isolation of ionic, atomic and
even small molecular species. Considerations of both top-
ology and orbital rehybridisation give the fullerenes their
unique chemical properties.
Size differences
While the fullerenes are a distinct allotrope of carbon,
there is considerable variation within the family: the
cages can consist of different numbers of carbon atoms,
leading to different shapes and sizes. This increases their
versatility and gives researchers considerably greater free-
dom in tailoring the molecules’ properties. C60 is the smal-
lest stable fullerene which obeys the isolated pentagon
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rule (IPR) – its football-like truncated icosahedron struc-
ture (Ih symmetry point group) leads to every carbon
atom environment being identical, as elegantly shown
by the sole peak in the13C NMR spectrum (Fig. 2a).
This is in contrast to the ﬁve peaks for C70 (Figs. 2b and
c). Higher fullerenes exist, with adherence to the IPR a
necessity for stability. Bigger cages have an increased
number of isomers. This variation leads to differences in
shape and symmetry, and makes isomeric isolation difﬁ-
cult and costly.34
These differences in size and shape have signiﬁcant
effects on both the optical properties (Fig. 3) and chemi-
cal behaviour of the fullerenes. Solubility decreases with
increasing cage size.8 Fullerenes are generally soluble in
aromatic hydrocarbons and halogenated solvents, as well
as CS2.
9, 10 The ﬁnal size effect regards the reactivities of
the fullerenes. The primary driving force for addition
reactions is the relief of strain in the cage structure
and the ensuing return to local sp3 hybridisation.
Thus, fullerenes generally exhibit reduced reactivity as
the cage size increases; the departure from a curved,
strained surface to a more planar, graphitic topology
explains this.11
Synthesis
The mechanism of fullerene formation still remains a
mystery despite numerous attempts at explanation. 12
That has not, however, precluded our ability to produce
tens of tons of C60 per year.
13 This process put forward
by Murayama et al. for Frontier Carbon Corporation
(FCC) gives a soluble product mixture of 60% C60 and
25% C70, while the remaining 15% are higher fullerenes
up to C96. These are soluble in the organic solvents used
for fullerene separation and constitute only 20% of the
solid mass retrieved from the reaction chamber; the
remaining 80% is insoluble carbonaceous soot. This com-
pares favourably to the ﬁrst process to produce fullerenes
on the gram scale, the standard Krätschmer–Huffman arc
discharge, where the fullerene content was ≤ 5% and the
relative intensities of the fullerene species were similar.14
In this now-standard process, electrical discharge creates
a plasma which evaporates graphite in a helium atmos-
phere. That pioneering work built upon the initial discov-
ery of C60 5 years earlier where it was produced using a
low-yield laser ablation method.15 While it is now evident
that the production of C60 and C70 has been successfully
scaled-up, thus signiﬁcantly driving down their cost,4
access to large quantities of higher fullerenes still remains
an issue. Even more pressing is the difﬁculty in scalably
synthesising endohedral fullerenes, something of crucial
importance to potential future medical technologies.
Both size and synthesis issues impact the processabil-
ity of different fullerenes and, as will be seen, their
derivatives. Practical considerations of solubility,
1 1,3,5-Cyclohexatriene and [5]radialene sub-units, as found
in C60 (double bonds are emitted for clarity)
2 13C nuclear magnetic resonance (NMR) spectra of C60 a
and C70 b. Every carbon environment in C60 is identical
(all are equally strained in the spherical structure), while
there are ﬁve environments in C70, corresponding to
each successive, increasingly strained ‘layer’ of carbon
atoms away from the equatorial plane c. NMR spectra
were taken in carbon disulphide (CS2) on a Bruker AVIII
400MHz machine
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reactivity and scalable production methods play a great
role in determining whether a fullerene-based technol-
ogy can feasibly go to market; this is of particular
importance in the pharmaceutical industry and will be
touched upon throughout this review.
Exohedral functionalisation
The number of different reactions which have been car-
ried out on fullerenes is immense and barely a fraction
of them can be covered in this review.5 A selection of
four reactions which are particularly relevant to the
development of water-soluble fullerene derivatives for
biomedical applications will be highlighted herein.
Each will be examined in more general terms, with
speciﬁc examples appearing later. It should also be
noted that, unless stated otherwise, all reactions in this
section were done with C60.
The ﬁrst two reactions, amination and hydroxylation,
are each simple additions of a small polar functional
group to the fullerene cage. They both give reasonable
water solubilities but suffer from a total lack of control
of the precise number of functional groups which are
added to the cage.6 This is a major drawback for their
deployment as pharmaceutically relevant reactions as
this industry requires stringent control over its chemical
structures; each batch of product synthesised must be as
pure as possible, not only with respect to reagent
impurities.
The second two reactions – the Prato17 and Bingel18
reactions, named after their discoverers – are very popular
fullerene reactions, lauded for their ability to introduce a
vast array of complex functional groups to the fullerene
derivative in simple, one-pot processes. For this reason,
they have been employed in numerous application areas
besides water solubilisation.16 They are such robust reac-
tion protocols that they have also been applied to functio-
nalise CNTs. 19,20
Amination
One of the ﬁrst reactions to be carried out with fullerenes
was the direct amination of C60.
21 Wudl et al. simply
mixed C60 in a series of neat aliphatic primary amines
(n-propylamine, t-butylamine7 and dodecylamine) for
16–24 h, observing a colour change through blue/green
to brown. Precise elucidation of the number of adducts
in each reaction was not carried out, although an average
of six adducts was calculated8 for the n-propylamine reac-
tion. Elsewhere, reaction of C60 and C70 with neat, excess,
shorter chain primary and secondary amines (methyl-
amine and diethylamine) yielded products containing up
to 14 amine groups, as shown by mass spectrometry.22
Amination is an important reaction as it can lead to
water-soluble derivatives, as demonstrated by the reaction
of C60 with ethylenediamine.
21 The reaction mechanism
for amination of C60 is described in Fig. 4; addition
occurs across the [6,6] bond. Interestingly, a density func-
tional theory-based study has shown that the addition of
methylamine to the larger C80 cage takes place across the
[6,5] bond, with subsequent additions preferentially
occurring at [6,5] bonds in pentagons adjacent to the pre-
vious attachment site.24 This could have useful conse-
quences for the control of addition reactions to larger
fullerenes.
Hydroxylation
The synthesis of polyhydroxylated fullerenes (inter-
changeably called PHFs, fullerenols and fullerols9) was
ﬁrst achieved by Chiang et al.25 who mixed C60 and C70
in an aqueous solution of sulphuric acid and nitric acid
(optimum temperatures of 85–115WC). An average of
14–15 hydroxyl groups attached to each cage. The more
common method of hydroxylation involves stirring a sol-
ution of fullerenes in basic conditions. An exceptionally
quick reaction time (three minutes) can be achieved by
addition of excess aqueous NaOH to a benzene solution
of C60 in the presence of a small amount of tetrabutylam-
monium hydroxide, which acts as a phase-transfer cata-
lyst.26 Other quaternary ammonium hydroxides were
tested as catalysts with a markedly less pronounced effect;
the reaction took over 96 h in the absence of any catalyst.
The average number of hydroxyl groups was 26, greater
than the product from the acidic conditions of Chiang
et al., and this corresponded to an increased water solubi-
lity: the greater the number of hydrogen bond donors, the
greater the water solubility.
Despite the lack of precise control on the number of
addends, hydroxylation has proved a very popular
method of water solubilisation for both empty-cage and
endohedral fullerenes, and a wide range of synthetic
routes exist. 27,28
Prato reaction
This 1,3-dipolar cycloaddition of an azomethine ylide to a
fullerene gives a stable pyrrolidinofullerene product in
good yield. The ylide is a reactive intermediate produced
in situby the condensation of an α-amino acidwith an alde-
hyde or ketone, followed by decarboxylation (Fig. 5). The
thermodynamically favoured product of this reaction
involving C60 has the pyrollidine ring attached across a
[6,6] bond, with the kinetically favoured attachment
being across the [6,5] bond. Cardona et al.30 showed that
these products were reversed (i.e. [6,6] adduct is kinetically
favoured, [6,5] thermodynamically) in the case of endohe-
dral metallofullerenes (EMFs) M3N@C80, leading to
drastically different electrochemical behaviour.
The beauty of the Prato reaction is its ability to intro-
duce multiple functional groups to the fullerene moiety.
Referring to Fig. 5, groups R1, R2 and R3 can be tailored
to the desired function. In particular, the possible
3 The absorption spectra of the fullerenes change as the
size of the conjugated system increases: with slight vari-
ations depending on solvent, solutions of C60 are an
intense purple colour a, C70 red like wine b and C84 a
green-yellow. (All above solutions in toluene). Generally
speaking, the gap between the highest occupied molecu-
lar orbital and the lowest unoccupied molecular orbital
decreases with increasing cage size leading to optical
absorptions of lower energy, i.e. longer wavelength7
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variability of R1 means the Prato reaction can proceed not
only with primary but also secondary amino acids, thus
expanding the reaction’s applicability.
In contrast with the lack of control of the number of
addends in the amination and hydroxylation reactions,
good control can be achieved with the Prato reaction
by tuning the stoichiometry of reagents and reaction
time. Given that all [6,6] bonds on pristine C60 are iden-
tical, all mono-adducts of the same addend are likewise
identical. Signiﬁcant regioisomerism and lack of control
is, however, introduced on addition of a second addend
to form a bis-adduct.31 The second addend has a choice
of nine different [6,6] bonds at which to attach, as
shown in Fig. 6, leading to a possible eight regioisomers
(presuming the second addend is the same as the ﬁrst).
The difﬁculty in product puriﬁcation which this regioi-
somerism introduces is compounded by the cis/trans
isomerism present in pyrollidinofullerenes due to the
chiral carbon atoms in the ring either side of the
amino group (provided R2, R3 = H). This could be
of signiﬁcance when looking at using fullerene deriva-
tives in biomedical contexts as regioisomerism is
known to have a signiﬁcant effect on pharmaco-kinetics
and -dynamics. 32 In a critical study – signiﬁcant in
deciding which route to take to well-deﬁned fullerene
multi-adducts – Lu et al. concluded that bis-addition
using the Prato reaction cannot be as well controlled
as with the Bingel reaction.33 However, Zhou and
4 Amination mechanism of C60. The ﬁrst step is single-electron transfer (a fast process) to produce the C60 anion radical which
has a characteristic green colour.23 Radical recombination gives a zwitterion which can be stabilised by proton transfer to
give the ﬁnal product (a slow process giving a brown solution)
5 Prato reaction mechanism (after Scarel29). Initial attack of the aldehyde/ketone’s polar carbonyl group by the nitrogen lone
pair of the amino acid leads to the expulsion of water, before decarboxylation gives the reactive ylide intermediate
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Wilson34 used a rigid tether between two azomethine
ylides to controllably and selectively synthesise regioiso-
meric bis-adducts. This technique has found plenty of
use with the Bingel reaction, but with the Prato reaction
the chiral centres in the pyrrolidine rings introduce
stereoisomeric complications.
Bingel reaction
Arguably themost popular reaction for exohedral functio-
nalisation of fullerenes, this cyclopropanation involves the
addition of an α-halo ester/ketone to the cage under
strongly basic conditions (1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) andNaH aremost commonly used), yielding
a methanofullerene.18 The mechanism of the classic reac-
tion using a bromomalonate is given in Fig. 7. As with
the Prato reaction, functional groups R1 and R2 can be
speciﬁcally tailored to purpose; on the downside, the
issue of regioisomerism in bis-adducts is also common.
The popularity of the Bingel reaction, however, arises
from versatile modiﬁcations of the original reaction, not
least the ability to produce the halogenated intermediates
in situ, which negates the need for their often time-consum-
ing puriﬁcation. Iodine35 and tetrabromomethane
(CBr4)
36 have been effectively used for this purpose, with
reaction yields of generally 30–60%. Also, unlike the
Prato reaction which proceeds at  120 WC, the Bingel
reaction needs mild room temperature conditions.
Hirsch et al.37 addressed the issue of regioisomerism
arising from the Bingel reaction using a somewhat circui-
tous route to well-deﬁned C60 tris-adducts. After ﬁrst
synthesising the expected range of bis-adducts, the
trans-3 (12.0% yield) and e (15.5% yield) regioisomers
were isolated and further cyclopropanated. This yielded
the tris-adducts seen in Fig. 8 in an impressive 40%
yield. The tris-adduct from the trans-3 bis-adduct has all
attachments at the trans-3 position (trans-3,trans-3,
trans-3) and so D3 symmetry; that from the e bis-adduct
has all attachments at the equatorial positions (e,e,e)
and so C3 symmetry. A visible colour difference was
also observed: the C3 product being a more intense
orange compared to the red of the D3 product. These
results indicate that functionalisation history affects the
subsequent addition of other groups onto the fullerene
cage and so can be used to control spatial
functionalisation.
Tethered moieties can also be used to direct functio-
nalisation to speciﬁc points on the cage. Sigwalt
et al.38 successfully used tert-butyl(trialkoxy)silane tris-
malonates to synthesise e,e,e tris-adducts (Fig. 9) in 8–
26% yield. This method gives a notably increased yield
in pure e,e,e tris-adduct ﬁnal product compared to the
functionalisation route via isolation of bis-adducts of
Hirsch et al. above. Another attempt at e,e,e tris-adduct
isolation, involving a protection–deprotection sequence
based on the high-temperature (180WC) Diels–Alder
reaction, achieved a meagre 4.2% yield in much harsher
conditions.39
Fullerene derivatives with even more adducts might be
desired for biomedical applications as a greater number of
polar groups should give increased solubility. Hexakis-
adducts of high Th symmetry with structurally complex
malonates10 have been synthesised in good yield (40–
68%) by Li et al.40 who used a deceptively simple modiﬁ-
cation of the standard Bingel reaction. Instead of stoi-
chiometric ratios speciﬁc for the desired product, they
found that a 100-fold excess of the halogenating agent
(in this case, CBr4) preferentially yielded the hexakis
adduct.
The introduction of carboxylic acid groups to the full-
erene cage is an effective way of increasing the water solu-
bility. However, as in the exemplary case of fullerene
malonic acids,41 the carboxylic acid group is often intro-
duced by base hydrolysis after the Bingel reaction has
already taken place with a neutral diethyl malonate, as
there would otherwise be unwanted acid base interaction.
This represents a general issue of how to apply the Bingel
reaction when incorporating acidic and base-labile func-
tional groups. A work-around was discovered by Jin
et al. who scrapped the need for a basic catalyst.42 Instead
they used an amino acid (sarcosine) and DMSO to cata-
lyse the reaction in chlorobenzene (PhCl) solution
(Fig. 10), giving methanofullerene mono adducts in
good yield (33–53%). A potential down side is that rela-
tively large amounts (20 equivalents) of malonate were
needed, so the synthesis of these must be scalable with
that of the fullerene derivatives.
Endohedral functionalisation
The relatively inert interiors of the fullerenes render them
able to capture atoms and atomic clusters within. The
standard notation X@C2n was introduced by Chai
et al.43 to denote endohedral fullerenes, where X is the
incarcerated species and n speciﬁes the cage size. Recently,
a ‘molecular surgery’ approach, using a series of cage-
opening and -closing chemical reactions, has led to the
encapsulation of single molecules of hydrogen and water
in C60 to give H2@C60 and H2O@C60 (60–78% incorpor-
ation, respectively).44 The focus of this section, however,
will be on the EMFs, which are synthesised by more
established procedures and have found extended use in
research on fullerenes for medical applications.11
6 Possible second addend addition sites (adapted after 31).
There are three sites in the same hemisphere as the initial
site of addition, giving rise to cis-regioisomers c1, c2 and
c3; two equatorial sites, e’ and e”; and four addition sites
in the other hemisphere, giving trans-regioisomers t1, t2,
t3 and t4
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Endohedral Metallofullerenes
This is a broad family of endohedral fullerenes where the
cage plays host to either one (monometallic) or two (dime-
tallic) metal atoms or a cluster of metal atoms with
another atom, often nitrogen. The presence of large
metal atoms within the cage leads to differing reactivities
and properties which can be exploited for numerous appli-
cations, including those in the biomedical realm.46 In that
7 Bingel reaction mechanism. Deprotonation by the strong base gives the nucleophilic malonate anion which then attacks the
[6,6] bond. Bromine is then expelled as cyclisation is completed
8 C60 diethyl malonate tris-adducts. Addition at the trans-3 positions imparts D3 symmetry and produces a red solution; at the
equatorial positions, C3 symmetry and an intense orange solution
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ﬁeld, the majority of literature covers the use of gadoli-
nium-containing EMFs as contrast agents (CAs) in mag-
netic resonance imaging (MRI).
Synthesis. Much like C60, the ﬁrst EMFs were syn-
thesised using expensive and low-yielding laser ablation.47
Adaptations of the now-standard Krätschmer–Huffman
arc discharge method have led to scaled-up synthesis of
EMFs: composite graphite rods containing the desired
metal oxide (most often lanthanide oxides) are used, how-
ever, yields are still generally less than 2% of the total car-
bonaceous material produced.12,49 The major product of
such a synthesis is monometallic fullerene, M@C82,
which has good solubility in common organic solvents
and so can be separated from other products using
HPLC. It should be noted that the ﬁrst step of EMF iso-
lation before HPLC separation is its extraction, using a
standard Soxhlet method, from the carbon soot mixture
by use of polar solvents such as dimethyl formamide
(DMF). This is because the incarcerated metal atom
does not sit centrally in the elongated cages of larger full-
erene cages, giving the molecule an overall electric dipole
moment. Kozlov et al.50 optimised this standard process
to produce Gd@C82 of excellent purity (99%).
Stevenson et al.51 synthesised Sc3N@C80, the ﬁrst tri-
metallic nitride template (TNT) EMF, in a marginally
better 3–5% yield by introducing a small amount of nitro-
gen to the arc reactor. Their synthesis was vastly improved
by Dunsch et al.52 whose ‘reactive gas atmosphere’ con-
cept – the addition of ammonia into the reactor – gave
EMFs as the majority fullerene product for the ﬁrst
time. The composition of the TNT EMFs can be general-
ised to XxYyM3−x−yN@C80, where X, YandM are differ-
ent metallic species. These species exist because the
nitride clusters have been found to stabilise the high-
symmetry Ih-C80 cage.
A further step towards commercial synthesis of TNT
EMFs was achieved by Bezmelnitsyn et al.53 whose
novel approach to arc discharge, they estimate, has
reduced the cost of lutetium-containing TNT EMF syn-
thesis by 70–80%. A three-fold increase in yield was
achieved by using a pyramidal three-phase AC arc dis-
charge setup (cf. the standard two-electrode DC setup)
along with a pure nitrogen atmosphere (negating the
need for expensive helium) and metal oxide powder injec-
tion with solid graphite electrodes.
Exohedral functionalisation. The exohedral functionali-
sation of EMFs is even less trivial than that of empty-cage
fullerenes.13 Entrapped metallic species transfer electrons
to the carbon cage, with this excess electron density inho-
mogeneously distributed over the cage, and even extend-
ing out of it – a phenomenon dubbed ‘spin leakage’. 55
This has profound effects on the chemistry of the
EMFs.46 Prato reactions have been carried out on
La@C82 to yield mono- and bis-adducts, with electron
paramagnetic resonance measurements showing slight
modiﬁcation of the electronic structure upon mono-
addition, and signiﬁcant modiﬁcation upon bis-
addition.56 Bingel cyclopropanation was used by Bolskar
et al.57 to isolate a derivative of the otherwise insoluble
Gd@C60. This is of value as the Gd@C60 fraction of
the arc discharge soot is more abundant than Gd@C82
but could never be isolated due to its insolubility. A 15-
fold excess of diethyl bromomalonate yielded primarily
the decakis-adduct, Gd@C60[C(COOCH2CH3)2]10,
which was hydrolysed to the water-soluble Gd@C60[C
(COOH)2]10. This has been investigated as an MRI CA.
Other Gd-EMF MRI CAs, which are examined later,
have primarily been hydroxylated to achieve water
solubility.
Fullerenes in medicine
Herein, a selection of water solubilisation methods are
ﬁrst covered in an attempt to discover which offer the
most promise as potential platforms for medical tools.
We then give a run-down of medical uses for which fuller-
enes have been investigated, offering a critical opinion as
to which seem to show the most promise.
Water solubilisation
Pristine fullerenes are highly hydrophobic and so cannot
be deployed in the body given that water is the primary
constituent of blood into which medicines are delivered
intravenously.14 Addition of hydrophilic, polar groups
which are capable of hydrogen bonding with water mol-
ecules are the key to achieving water solubility; in turn,
water solubility is the key to a longer retention time in
the bloodstream due to decreased recognition as a foreign
body by the immune system.
Covalent functionalisation is the surest way to produ-
cing fullerene-based systems viable for biomedical appli-
cation as the structures of such molecules can be
precisely deﬁned (using X-ray crystallography) and their
pharmaco-kinetic and -dynamic behaviour better under-
stood and ﬁne-tuned. This is in comparison with two
other methods of water solubilisation:
(1) Encapsulation in water-soluble hosts – Calixarenes
are a good example of this type;58
9 tert-Butyl(trialkoxy)silane-tethered cyclopropanation e,e,e
tris-adduct (2<n<4)
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(2) Supramolecular/covalent incorporation into water-
soluble polymers – Giacalone et al.59 give a good
overview.
The major issues with these two methods are: the lack of
deﬁnition of molecular structure in solution; inhomogeneity
of samples;15 and unpredictable side effects from the
water-solubilising component(s). Iwamoto and Yama-
koshi60 synthesised C60–NVP (Fig. 11) with one of the high-
est water-solubilities (7.8mM) of any fullerene derivative.
However, being a polymeric system, it contains a spread
of differently sized molecules ranging from 30 to 50 kDa,
which is not speciﬁc enough to be scaled up to pharma-
ceutical scale.
An easy route to water-soluble C60 was ﬁrst devised by
Lamparth and Hirsch41, who recognised the need to iso-
late single regioisomers for investigation in biomedical
studies. Thus, they took their previously synthesised C3
andD3 tris-adducts and hydrolysed them to the respective
malonic acids by stirring in 20-fold excess of NaH for 3 h
at 60WC. These products were very soluble, even in neutral
water, and bis- and mono-adducts were also hydrolysed to
conﬁrm that water solubility did indeed increase with the
number of carboxylic acid groups. These tris-adducts have
been extensively studied for a variety of biomedical appli-
cations16 but there is a fear that the malonic acid groups
10 C60 Bingel reaction in the presence of dimethyl sulphoxide (DMSO), with basic catalyst replaced by amino acid (adapted
from Jin et al.42). DMSO facilitates single-electron transfer from the amino acid to the fullerene to give the radical cation
and radical anion respectively. The fullerene anion then attacks a brominated active methylene, expelling the bromine
and forming a fullerenyl radical. Interaction between this and the amino acid radical cation from the ﬁrst step then ﬁnalises
cyclisation to give the desired methanofullerene
11 C60–N-vinylpyrrolidine (C60–NVP) derivative
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are actually unstable under physiological conditions, lead-
ing to cytotoxic side products.61
Another successful water solubilisation via the Bingel
reaction was achieved by Brettreich and Hirsch.62 Their
dendro[60]fullerene mono-adduct (Fig. 12) gave the high-
est water solubility to date (12 mM). It signiﬁes a different
approach to the water solubilisation of fullerenes as it uti-
lises the dendritic nature of the addend to introduce many
polar groups and hydrophilicity, rather than adding the
same small number of polar groups via multiple addends.
An early attempt to synthesise water-soluble fullerenes
via the Prato reaction was not completely successful.63
The introduction of two triethylene glycol chains off the
pyrrolidine ring of the mono-adduct (34% yield) gave a
poor upper limit to solubility of 3× 10−5 M in a 9:1
water-DMSO binary solvent. Positively, however, this
derivative showed promising anti-bacterial and anti-fun-
gal activity. Aroua et al. used the Prato reaction to syn-
thesise a versatile mono-adduct bis-carboxylic acid
building block (Fig. 13) which was made water soluble
(> 3mM) by subsequent PEGylation or reaction with
the peptide sequence, GABA-GPLGVRGA.17,64
Dynamic light scattering measurements conﬁrmed a
mono-modal distribution of aggregate particle diameter
of  10 nm. This small size and mono-modal distribution
is required for biomedical applications so that the fuller-
ene derivative can act efﬁciently and without unwanted
aggregation effects.
Hydroxylation is a very popular water-solubilisation
method despite its lack of speciﬁcity. In their synthesis
of Gd@C82(OH)x, Chen et al.
65 obtained a ﬁnal product
with a narrow distribution in the number of hydroxyl
groups by selectively collecting only a cropped portion
of HPLC fraction.
Diagnostics
Two non-invasive imaging techniques are investigated
below, with readers directed elsewhere for a comprehen-
sive discussion of such techniques.66
Magnetic resonance imaging
The paramagnetic gadolinium(III) ion (Gd3+) is used in
MRI CAs because its large magnetic moment and seven
unpaired, isotropically distributed 4f electrons (the high-
est number for any element) dramatically reduce the T1
and T2 relaxation times
18 of any surrounding water pro-
tons, thus giving increased contrast in images. 67,68 The
percentage change in T1 is greater than in T2 and so the
best visualisation is in so-called T1-weighted images.
69
In order for Gd3+ to enter the body, chelating agents
are used to strongly bind the ion; several different chelat-
ing agents are currently available on the market and are
used every day in hospitals across the world.70 However,
these chelating agents have limitations which it is hoped
Gd-EMFs can alleviate. First, there is evidence that the
highly toxic gadolinium ion can escape chelates in sufﬁ-
cient quantities to cause fatal damage to patients with
renal failure. 71,72 By capturing Gd3+ within a stable full-
erene cage, there is no chance of escape and so that pro-
blem is negated. Second, as shown below, the relaxivity
effects of Gd-EMFs can be over an order of magnitude
12 Dendro[60]fullerene mono-adduct
13 C60 mono-adduct bis-carboxylic acid building block for
water-soluble derivatives
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greater than clinically available chelate-based CAs, mean-
ing that lower doses can be administered for the same
improvement in image contrast.73 This might at ﬁrst
seem unexpected given that water molecules cannot
directly interact with the gadolinium ion as it is shielded
by the carbon cage, thus getting rid of all inner-sphere
contributions to the relaxivity. Sitharaman et al.74 found
that Gd@C60[C(COOH)2]10 and Gd@C60(OH)x form
larger aggregates19 as the pH of the aqueous solution
decreases. Thus they proposed that the large outer-sphere
relaxivities observed are due to the slow tumbling of the
aggregates formed.
Adding further evidence to this hypothesis, Zhang
et al.75 also observed a dependence of the relaxivities of
the Gd3N@C80[DiPEG(OH)x] on aggregate size. An
optimum PEG chain weight of 350 Da gave aggregates
of 95-,nm size and an r1 of 237 mM
−1 s−1 (2.4 T magnetic
ﬁeld), which compares very favourably to the r1 values of
low-molecular weight Gd3+-chelates which are typically
3–5 mM−1 s−1.76 Laus et al.77 note, however, that the for-
mation of aggregates of Gd-EMFs can be disrupted, and
so relaxivities reduced, by the addition of salts commonly
found in the body (e.g. phosphates). Relaxivities were
though still generally an order of magnitude greater
than commercially available chelates.
This phenomenon of exceptional r1 values is not lim-
ited to Gd-TNT EMFs, as Mikawa et al.78 obtained an
r1 value of 81 mM
−1 s−1 (1.0 T magnetic ﬁeld) using
Gd@C82(OH)x. Other examples of promising Gd-EMF
MRI CAs have been synthesised79,80 and Ghiassi et al.81
give a comprehensive outlook on the ﬁeld.
Zhang et al.82 synthesised two novel water-soluble
Gd-EMFs also containing scandium, which again showed
improved relaxivities compared to commercial agents.
ScxGd3−xN@C80Om(OH)n (where x = 1, 2;m ≈ 12;
n ≈ 26), respectively, gave r1 values of 20.7 and 17.6
mM−1 s−1. This is an important result as
ScxGd3−xN@C80 was synthesised in greater yields than
both Gd@C82 and Gd3N@C80, and was actually the
third most abundant fraction from the arc discharge
soot, after C60 and C70.
A remarkably high r1 relaxivity of 368.7 mM
−1 s−1
(1.5 T magnetic ﬁeld20) was achieved by combining pris-
tine Gd@C82 and water-soluble graphene oxide (GO).
83
π–π interactions between the GO and Gd-EMF are
thought to facilitate electron transfer between the two
and so help increase the observed relaxivity. While this
nanohybrid is an exemplary system for achieving high
relaxivities, it suffers from a lack of precise deﬁnition of
what comprises the sample (e.g. the number of fullerenes
per GO sheet).
Finally, Wang et al.84 utilised C60 as a central tethering
moiety for the attachment of 4–5Gd-DOTA21 chelates
(Fig. 14). While admirable for exploiting C60 as a three-
dimensional chemical anchor and achieving an improved
r1 relaxivity of 49.7 mM
−1 s−1, this novel derivative does
not solve the issue of gadolinium escaping from its che-
lated state.
Deploying EMFs as MRI CAs is without doubt one of
the most saturated spaces in biomedical fullerene
research. Given the signiﬁcant improvement in r1 relaxiv-
ity which Gd-EMFs offer when compared with currently
used Gd-chelates, and the lack of Gd-toxicity due to
incarceration within the fullerene cage, it seems likely
that this could be one of the ﬁrst places we see fullerenes
deployed as a biomedical tool. Improvements in synthesis
routes, however, need to be achieved – speciﬁcally, higher-
yielding arc discharge methods need to be scaled-up
and controllable exohedral functionalisation must be
achieved.
X-ray imaging
Wharton and Wilson85 ﬁrst developed a highly iodinated
C60 derivative (Fig. 15) for use as an X-ray imaging CA,
mimicking the highly iodinated and highly water-soluble
structure of commercially available Iohexol®. Using C60
as a three-dimensional central anchor, Bingel cyclopropa-
nation was initially used to add the highly iodinated
addend before four further cyclopropanations introduced
polar groups responsible for an impressive water-solubi-
lity of > 460mgmL−1.
In contrast22 to this exohedral introduction of multiple
iodine atoms, Miyamoto et al.86 investigated a range of
fullerenol EMFs as X-ray CAs – it was hoped that these
would abolish the need for iodinated agents, which can
cause severe issues for patients with an allergy to iodine.
The structures investigated – M@C82(OH)40 where M =
Dy, Er, Gd, Eu or Lu2 – unfortunately, however, did not
produce contrast comparable to that of commercially
available agents.
Therapeutics
Human immunodeﬁciency virus-1 (HIV-1) protease
inhibitor
The ﬁrst posited medical application of C60 was as an
inhibitor of human immunodeﬁciency virus-1 (HIV-1)
protease, as the fullerene core is ideally suited to interact
with the receptor site of the enzyme due to its hydro-
phobic surface and spherical shape.87 By blocking the
receptor site, the cleaving of proteins required for HIV
replication and infection can no longer take place. In
this initial work, Friedman et al. used water-soluble C60
derivatised with bis(phenethyl-aminosuccinate) before
suggesting, with the evidence of modelling, that direct
amine additions to the cage could give better
14 C60-(Gd-DOTA)n (n=4 or 5)
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performance. A further modelling study by Tzoupis et al.88
aimed to design fullerene derivative inhibitors by consider-
ing hydrogen-bond patterns, the regions of the receptor site
most important for binding and contributions to the bind-
ing free energy. Recent work by Strom et al.89 has shown
that C60-based amino acids can be further functionalised
and their inhibition capability tuned by adding specially
designed peptide sequences. Aside from inhibition of the
protease enzyme, Tanimoto et al.90 actually managed to
degrade and thus render inactive HIV-1 protease by irra-
diating (365 nm) sugar-functionalised C60 which had
docked in the enzyme. This photodynamic effect is dis-
cussed further below.
Antioxidants
The role of oxidative stress – the unregulated and exces-
sive proliferation of radicals, such as reactive oxygen
species (ROS), within the body – in the pathogenesis of
human disease cannot be overstated.91 While ROS, cre-
ated by the partial reduction of oxygen,23 are naturally
produced by metabolic processes within the body and
have even been found to play a key part in cellular signal-
ling, deviation from homeostasis due to an increase in
ROS levels24 or a decrease in inherent antioxidant capa-
bility leads to problems.93 Such problems include pro-
motion of tumour metastasis, 94 neurodegeneration95
and other degenerative diseases associated with aging. 96
Fullerenes have attracted much attention as potential
antioxidant therapeutic agents due to their high capacity
for radical quenching – they readily accept the lone elec-
trons of radicals into their extended conjugated system.
Beuerle et al.61 offer an excellent discussion on the efﬁca-
cies of various fullerene derivatives in quenching a range
of ROS. In groundbreaking work, Dugan et al.97 showed
that 40− 50mM solutions of tris-malonic acids C3 and
D3 eliminated all superoxide radicals generated in situ,
and that the C3 derivative in particular showed promising
neuroprotective behaviour thanks to its antioxidant abil-
ity.98 Further work from the same group showed that C3,
when administered to non-human primates with Parkin-
son’s disease, was responsible for improvedmotor function.
99 These results and a myriad other studies looking at C3
have established it as the poster-boy fullerene antioxidant,
thus arguably propelling the ﬁeld closer to market.61
Dendrofullerenes of ﬁrst and second generation (see
Figs. 16 and 12, respectively) were required in lower
doses than both C3 and D3 for effective superoxide
quenching, seemingly conﬁrming that mono-adducts pro-
vide better antioxidant functionality thanks to a more
intact conjugated system.100
Away from protection of the central nervous system
and only superoxide quenching, Yin et al.101 found that
PHFs offered better cytoprotection than bis-malonic
acid, C60(C(COOH)2)2. The protective effects of
Gd@C82(OH)22 were found to be greater than its
empty-cage C60 analogue, C60(OH)22 and both were
found to scavenge a range of physiologically relevant
ROS. The radical scavening ability of fullerenols has
even been used to treat lower back pain effectively.102
15 Highly iodinated and water-soluble C60 derivative for X-ray imaging
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Photodynamic therapy (PDT)
Photodynamic therapy (PDT) is lauded as an attractive
cancer therapy for localised smaller lesions and carci-
nomas, as well as an aid during surgery of larger masses,
thanks to its relative non-invasiveness, precise targeting
and lack of long-term side effects.103 It works by irradiat-
ing an intravenously administered photosensitising mol-
ecule at a particular wavelength, which excites it into its
very short-lived (nanosecond scale) ﬁrst excited singlet
state, S1. Non-radiative decay of this S1 state gives the
longer-lived (up to milli-second scale) triplet state, T1,
which is subsequently quenched.104 In the case of molecu-
lar oxygen, quenching by energy transfer leads to the for-
mation of a highly reactive and cytotoxic ROS: singlet
oxygen (1O2).
105 Thus, the effectiveness of PDT relies on
the evolution of singlet oxygen in areaswith a high density
of cancerous cells.
Fullerene derivatives hold great promise as PDT photo-
sensitisers due to their unprecedented efﬁciency of 1O2
formation – for C60 irradiated at 532 nm, this is unity.
106
There are, however, some drawbacks. The ﬁrst is that
C60 absorbs well in the UV range and poorly at the red
end of the electromagnetic spectrum; this matters as
these are the wavelengths of the light sources typically
used in PDT. The second potential drawback concerns
the effect of multiple functionalisation of the fullerene
cage. Hamano et al.107 showed that increasing the number
of addends decreased the efﬁciency of 1O2 production. At
the extreme end, a PHF exhibited zero photosensitisation.
A ﬁnal drawback is the solvent dependency of 1O2 gener-
ation. Yamakoshi et al.108 showed that, while 1O2 is easily
generated in non-polar solvents, O.−2 and OH
. are the pre-
ferential products in polar solvents such as water and that
these are the species responsible for DNA cleavage in
physiological conditions, thus casting shadow over the
precise mechanism(s) of PDT. Readers are directed to
the review of Mroz et al.109 for a fuller treatment of this
topic.
Chemotherapy
PHFs are prevalent in the literature on cancer thera-
peutics, despite the speciﬁcs of their mechanism of action
not being fully understood. Kang et al. and Pan et al.
provided a detailed mechanistic insight into the action
of Gd@C82(OH)22 on pancreatic tumour metastasis,
25
concluding that the amphiphilic nature of the PHF
(hydrophobic cage carbons and hydrophilic hydroxyl
groups) led to speciﬁc binding and enzymatic inhibition.
110,111 Liu et al. recognised that, while sharing the same
number of hydroxyl groups, Gd@C82(OH)22 outper-
formed C60(OH)22 in the inhibition of breast cancer
metastasis. 112 This is a good demonstration of the effect
of the incarcerated species in EMFs on their reactivity,
structure and subsequent function. Chen et al. found the
antineoplastic activity of Gd@C82(OH)22 was consider-
ably greater than that of commonly used cis-platin, thus
adding weight to the claim for fullerenes to be used as che-
motherapeutic agents.113
Theranostics
A distinct selling point of the fullerenes is their ability to
combine multiple functionalities, thus making them
viable theranostic26 platforms.114 Theranostics offers an
attractive route to personalised nanomedicines where
exposure to treatment can be monitored and thus tailored
for each patient individually.115,116
Photoacoustic imaging and photothermal therapy
This is a rather novel example of nanoparticles exhibiting
useful theranostic qualities, with beneﬁts of deeper tissue
penetration and lower cost when compared with more
traditional imaging modalities, e.g. MRI.117 Fullerenols
(C60(OH)xOyNaz) and carboxy-fullerene tris-adducts
(C60(C(COOH)2)3) were exposed to low-intensity near-
IR laser irradiation (10 mJ cm−2) in both in vitro and in
vivo27 studies. A scanning ultrasound detection system
detected a popping sound arising from the bursting of
mesothelial lung carcinoma (A549) cells due to induced
local heating of at least 4 WC. Thus, not only were cancer
cells destroyed, but the process could also be tracked by a
cheap, non-invasive imaging technique using a laser
power well within safety limits.
Brachytherapy, chemotherapy and dual-modal imaging
Shultz et al. synthesised a novel theranostic platform for
MRI and brachytherapy28 of brain tumours wherein
16 First generation water-soluble dendro[60]fullerene
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Gd3N@C80 (water solubilised by both carboxyl and
hydroxyl groups) was covalently linked to the DOTA che-
lating agent labelled with radioactive β-emitter,177Lu.29,118
Retention time in the tumour was good, allowing for good
T1-weighted imaging and effective delivery of brachyther-
apy. In a similar vain,177LuxLu3−xN@C80, with the
radiolabel within the fullerene cage, was developed by the
same group.119 Fears of β decay destroying the fullerene
cage were alleviated as there appeared to be little evidence
of it after one half-life (6.7 days).
In the ﬁeld of multi-modal imaging, Iezzi et al.120 syn-
thesised mixed-metal TNT EMFs, Lu3−xMxN@C80 (M
= Gd or Ho), where the lutetium atom provided X-ray
imaging contrast on top of the MRI contrast provided
by M. This is a promising result as these mixed-metal
TNT EMFs were actually synthesised in higher yield
than the mono TNT EMFs, e.g. Lu3N@C80. Another
multi-modal imaging platform has been developed by
Luo et al. for combined positron emission tomography
(PET) and MRI.121 Exohedral addition of 124I to
hydroxylated Gd3N@C80 conferred the PET ability
although, as with the X-ray CA of Wharton et al.,85 iod-
ine must be stably attached to the cage to avoid allergic
reactions. A lack of iodine uptake in the thyroid gland
seemed to suggest good stability of this molecule, giving
it promise as a future dual-modal imaging tool.
Toxicity
The toxicity of fullerenes and their derivatives is a hotly
debated topic amongst both researchers and regulatory
bodies.122,123 Particularly when dealing with synthetic
routes to potential pharmaceutical products, low levels
of genotoxic impurities will be introduced but must be
minimised. 124 As has been shown in the preceding sec-
tions, aggregation can have a great effect on the efﬁcacy
of administered nanoparticles30 and its effects in physio-
logical systems must be understood.125
Kyzyma et al.126 showed that aqueous solutions31 of
C60 had no toxic effects on Chinese-hamster V79 cells.
However, cytotoxicity of C60 in aqueous solution,
mediated by singlet oxygen production, was seen in
another study.127 Most importantly, this study found
that cytotoxicity is a sensitive function of the number of
functional addends attached to the cage, with increased
exohedral functionalisation decreasing cytotoxic effects
by over seven orders of magnitude. This is in keeping
with the results of Hamano et al.107 discussed earlier.
Gao et al.128 showed that C60(OH)24−26 presented no
acute or chronic toxic effects in model organisms from
four different kingdoms;32 on the contrary, there was evi-
dence of increased growth and extended lifespan, which
could have profound effects in environmental research
areas such as biofuel production. With regard to cancer
therapy, the antioxidant ability of C60(OH)24 has been
shown to modulate cytotoxic effects of chemotherapeutic
agent, doxorubicin (DOX), which induces ROS-mediated
oxidative stress. 129,130
Upon intravenous administration of future fullerene
derivatives, the pharmaceutical must efﬁciently perform
its function at the desired site, rather than just circulate
throughout the body without speciﬁcity. Thus, a ﬂagship
targeted fullerene system was synthesised by Fan et al.
who used a folic acid ligand to target tumour cells.131 Che-
motherapy was delivered on-site by DOX as well as PDT
thanks to the fullerene moiety. In an elegant twist, the
intracellular release of DOX could be tracked as its ﬂuor-
escence was quenched by C60’s excellent afﬁnity for
electrons.
Concluding remarks
This review has taken a holistic approach to the deploy-
ment of fullerene derivatives in biomedical contexts.
The unique electronic structure of a fullerene cage is
shown to be the basis of its salient properties. A num-
ber of exohedral synthesis protocols have been critically
examined, identifying the need for reproducible and
scalable methods which yield well-deﬁned addition pat-
terns, in line with requirements of the pharmaceutical
industry. Endohedral fullerenes remain a relatively exo-
tic commodity; despite their numerous varieties and
subsequent biomedical applications, even gram-scale
quantities are hard to produce. Effective methods of
water solubilisation have been critically evaluated,
taking into account the need for well-deﬁned addition
patterns. The highest water-solubility to date has been
achieved by a mono-functionalised dendrofullerene via
the popular Bingel reaction, and this same reaction pro-
tocol proves robust for synthesising multi-adduct
derivatives with well-deﬁned structure. With this knowl-
edge of product synthesis, applications of fullerene
derivatives in diagnosis, therapy and theranostics were
discussed. The literature on fullerenes as MRI CAs
and antioxidants is vast and these appear to be very
likely to make it to market soonest, given the marked
improvements on technologies currently used in-clinic.
Novel multifunctional theranostic platforms, however,
demonstrate the fuller beauty and power of nanotech-
nology when applied to medicine. In spite of cytotox-
icity arising from the efﬁcient generation of singlet
oxygen, fullerenes seem to exhibit little toxicity in
their functionalised form.
As with all vying nanomaterials, if fullerenes are to
reach the pharmaceutical market, and if fullerene-based
nanomedicine132 is to ﬁnd ubiquitous, daily application,
then an understanding of the fundamental physical and
chemical behaviour of these fascinating molecules
necessarily precedes their technological exploitation.33
Unlike other nanomaterials – such as CNTs,137
graphene,138 quantum dots (QDs) 139 and superparamag-
netic iron oxide nanoparticles (SPIONs)140 – there is not
an inherent heterogeneity of the base product. Each full-
erene has a precisely deﬁned structure in three-dimen-
sional space. The importance of this cannot be
overstated as, in drug discovery, it is the molecular struc-
ture which pharmaceutical companies patent. Thus,
there is a signiﬁcant distinction between fullerenes
and graphene (whose sheets are of different size and ter-
mination), CNTs (whose length and chirality vary) and
QDs and SPIONs (whose morphologies and topogra-
phies vary).
The beneﬁts conferred through using fullerenes as
medical tools could be immense, and it is the author’s
belief that they should and will soon be on the market.
This will, however, require further interdisciplinary col-
laborations and a willing dialogue between academia
and the pharmaceutical industry.
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Notes
1. Differentiated from benzene due to the difference in
bond lengths: the [6,6] bonds (double) between adja-
cent hexagons are 1.38 Å, while the [6,5] bonds
(single) which form the borders between hexagons
and pentagons are 1.45 Å.2
2. This strain accounts for approximately 80% of the
heat of formation of C60.
3
3. It is worth mentioning at this point that the primary
technique used to separate fullerenes from one
another is high performance liquid chromatography
(HPLC). Careful selection of the stationary phase
and solvent system can lead to good separation of
not only different sized cages, but also isomers con-
taining the same number of atoms.6
4. C60 can now be easily bought in large quantities at a
price comparable to any standard laboratory chemi-
cal. MER Corporation of Arizona, USA sells 99+%
pure batches of . 100 g at $20 per gram. As a good
example to see how the price and rarity increases
with cage size, the same company sells C70 of the
same purity for $325 per gram, up to 25 g (Prices cor-
rect as of June 2016).
5. Readers are directed to the excellent monograph by
Hirsch and Brettreich16 for a more complete over-
view of the library of fullerene reactions.
6. The ‘small polar functional group’ for amination
here refers to the addition of methylamine.
7. Actually 1:3 t-butylamine:DMF.
8. Based on the ratios H:C and H:N.
9. The fact that there is no consensus on the name of
this type of derivative should give an idea as to the
lack of speciﬁcity associated with its structure and
thus deﬁnition. This could conceivably cause regulat-
ory issues and is a representative example of one of
the stumbling blocks to fullerenes reaching the
pharmaceutical market.
10. Compared to the simplicity of the prototypical
diethyl malonate used in Bingel reactions.
11. Readers are directed to the review of Popov et al.45
for a broader and more comprehensive outlook on
the synthesis, properties and applications of endohe-
dral fullerenes.
12. EMF yields are found to be dependent on many
different parameters in the arc discharge reactor,
with a strong dependence on the pressure of the He
atmosphere.48 Reactor size thus obviously has a
major effect, as do rod size, distance between rods
and current.
13. Researchers have attempted to make sense of this
complex ﬁeld in both theory54 and experiment.
14. The favoured method of administering medicines as
it is fastest and gives 100% bioavailability of the
administered species.
15. This is particularly true when long-chain hydrophilic
polymers are involved and control over the precise
length of polymer chains is impossible. While more
ethylene glycol units, for example, will lead to an
increased solubility in polyethylene glycol (PEG)-
based systems, the pharmaco-kinetic behaviour
grows in complexity with increasing chain length
due to increasing size and conﬁgurational entropy
of the polymer chain. With a mixture of chain lengths
in the sample, predicting behaviour within the body
becomes even more difﬁcult.
16. A full list would warrant further discussion beyond
the scope of this review, so readers are directed to
the extensive list offered by Beuerle et al.61
17. Each letter in this sequence corresponds to a differ-
ent amino acid building block: G = glycine; A = ala-
nine; B = asparagine or aspartic acid (ambiguous);
P = proline; L = leucine; V = valine; R = arginine.
18. Thus increasing the relaxivities, respectively r1 and r2.
19. Diameter increase from 30–90 to 600–1000 nm.
20. An even higher r1 of 439.7mM
−1 s−1 was seen at 4.7 T.
21. DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid)
22. Pun not intended.
23. There are many ROS but two of the most studied are
the superoxide (O.−2 ) and hydroxyl (OH
.) radicals.
Reduction of molecular oxygen yields the superoxide
radical (O2+ e−O.−2 ) which can dismutate to
hydrogen peroxide (2H+ + 2O.−2  H2O2 +O2),
which can then be fully reduced to water or partially
reduced to the hydroxyl radical (H2O2  2OH.).92
24. This increase can be a result of endogenous gener-
ation (i.e. standard cellular activity) or exogenous
sources (e.g. through smoking tobacco).
25. Through a combination of in vivo, in vitro and in silico
observations.
26. Capable of both therapeutic and diagnostic
functions.
27. However, given the lack of a targeting moiety on the
fullerene cage, the in vivo study saw the fullerenols
encapsulated within functionalised silica or chitosan
nanoparticles.
28. Delivery of a radioactive source within the body so as
to allow localised tumour targeting with minimal-
radiation side effects cf. traditional radiotherapy
using external X-ray sources.
29. 177Lu also emits γ radiation which could be detected
by, for example, single-photon emission computed
tomography (SPECT) for imaging purposes.
30. Although the size and length of an individual macro-
molecular fullerene might be well characterised, the
average size and charge of many of them agglomer-
ated together will vary from solvent to solvent, and
could well lead to different toxic behaviour.
31. C60 was ﬁrst dissolved in N-methylpyrrolidine which
also showed no cytotoxicity.
32. These were: algae (Pseudokirchneriella subcapitata);
a plant (Arabidopsis thaliana); a fungus (Aspergillus
niger); and an invertebrate (Ceriodaphnia dubia).
33. Science aside, the opinions of the public and key
players in both policy and business (who may not
have a specialist background) cannot be ignored.133
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Surveys have shown that the UK and US public view
medical applications of nanotechnology in a less
favourable light than energy applications. 134 In one
study, industry perceives fewer risks associated with
nanotechnology than the public, and so does not
enforce the regulations the public expects of such
an industry.135 This is likely to change in the near
future as stricter deﬁnitions of a nanomaterial have
been implemented by the European Union and
include fullerenes within their scope.122,136
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